GOSS stock forecast
Our latest prediction for Gossamer Bio, Inc.'s stock price was made on the June 23, 2020 when the stock price was at 12.76$.
In the short term (2weeks), GOSS's stock price should underperform the market by -1.69%. During that period the price should oscillate between -10.00% and +10.86%.
In the medium term (3months), GOSS's stock price should underperform the market by -4.07%. During that period the price should oscillate between -39.13% and +27.92%.Get email alerts
Create a solid portfolio with GOSS
About Gossamer Bio, Inc.
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 25, 2015 and is headquartered in San Diego, CA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -3.26$ per share.
The book value per share is 7.29$
Three months stock forecastJune 23, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|